Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3247 |
Name | rhabdomyosarcoma |
Definition | A skeletal muscle cancer that arise from skeletal muscle progenitors. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer muscle cancer skeletal muscle cancer rhabdomyosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | AZD8055 + Selumetinib | rhabdomyosarcoma | not applicable | detail... |
Unknown unknown | BMS-754807 | rhabdomyosarcoma | not applicable | detail... |
Unknown unknown | Dasatinib | rhabdomyosarcoma | not applicable | detail... |
Unknown unknown | Cisplatin + YM155 | rhabdomyosarcoma | not applicable | detail... |
Unknown unknown | JQ1 | rhabdomyosarcoma | not applicable | detail... |
Unknown unknown | TAS4464 | rhabdomyosarcoma | not applicable | detail... |
Unknown unknown | Prexasertib | rhabdomyosarcoma | not applicable | detail... |
NRAS Q61H | Alpelisib + Binimetinib | rhabdomyosarcoma | sensitive | detail... |
Unknown unknown | SP-2509 | rhabdomyosarcoma | not applicable | detail... |
NRAS Q61H | Rigosertib | rhabdomyosarcoma | sensitive | detail... |
HRAS Q61K | Rigosertib | rhabdomyosarcoma | sensitive | detail... |
NRAS wild-type | Rigosertib | rhabdomyosarcoma | sensitive | detail... |
HRAS wild-type | Rigosertib | rhabdomyosarcoma | sensitive | detail... |
NRAS Q61H | Rigosertib + Trametinib | rhabdomyosarcoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT01241162 | Phase I | Decitabine | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | Completed | USA | 0 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01446809 | Phase I | Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib | Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01518413 | Phase I | Irinotecan + Sorafenib | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Completed | USA | 0 |
NCT01661400 | Phase I | Cyclophosphamide Thalidomide | Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT01871766 | Phase II | Bevacizumab + Cyclophosphamide + Sorafenib Dactinomycin + Vincristine Sulfate Cyclophosphamide + Dactinomycin + Vincristine Sulfate | Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery | Active, not recruiting | USA | 0 |
NCT02013336 | Phase I | Cyclophosphamide + MM-398 | Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT02095132 | Phase Ib/II | Adavosertib + Irinotecan | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02100891 | Phase II | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | Active, not recruiting | USA | 0 | |
NCT02303028 | Phase Ib/II | Pazopanib + Topotecan | Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours | Active, not recruiting | CAN | 0 |
NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Active, not recruiting | USA | CAN | 0 |
NCT02372006 | Phase Ib/II | Afatinib | Trial of Afatinib in Pediatric Tumours | Completed | USA | CAN | 10 |
NCT02390752 | Phase Ib/II | Pexidartinib | PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) | Recruiting | USA | 0 |
NCT02446431 | Phase I | Cyclophosphamide Bevacizumab Temsirolimus Valproic acid | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | Recruiting | USA | 0 |
NCT02567435 | Phase III | Cyclophosphamide + Dactinomycin + Vincristine Sulfate Temsirolimus Irinotecan | Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | Recruiting | USA | CAN | 3 |
NCT02574728 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | Recruiting | USA | 0 |
NCT02644460 | Phase I | Abemaciclib | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Recruiting | USA | 0 |
NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Recruiting | USA | 0 |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02890758 | Phase I | ALT-803 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Recruiting | USA | 0 |
NCT02982941 | Phase I | MGA271 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Completed | USA | 0 |
NCT03139331 | Phase I | Irinotecan + Pazopanib + Temozolomide | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | Completed | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | 1 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03213678 | Phase II | LY3023414 | PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT03233204 | Phase II | Olaparib | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03245151 | Phase Ib/II | Everolimus + Lenvatinib | Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors | Recruiting | USA | CAN | 1 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Recruiting | USA | 3 |
NCT03441360 | Phase II | Eribulin | Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) | Recruiting | USA | 0 |
NCT03458728 | Phase Ib/II | Copanlisib | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Recruiting | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT03709680 | Phase I | Irinotecan + Palbociclib + Temozolomide | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | Recruiting | USA | 0 |
NCT04095221 | Phase Ib/II | Irinotecan + Prexasertib + Temozolomide | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | Recruiting | USA | 0 |
NCT04299113 | Phase I | Mocetinostat + Vinorelbine | Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma | Recruiting | USA | 0 |
NCT04469530 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) | Recruiting | USA | 0 |